| Research Peptide APIs for Regulatory Market | |
|---|---|
| Product Name | US-DMF Time Point |
| Linaclotide | Before the end of 2019 |
| Ganirelix | Before the end of 2019 |
| Degarelix | Before the end of 2020 |
| Exenatide | Before the end of 2021 |
| Teduglutide | Before the end of 2021 |
| Cetrorelix | Before the end of 2021 |
| Semaglutide | Before the end of 2022 |
Other Polypeptide APIs Products
| Polypeptide APIs Products |
| US-DMF LIST |
| Beauty peptides |
| Chinese cGMP APIs |
| Mexico Registered APIs |
| Research Peptide APIs for Regulatory Market |
| Polypeptide Preparation |
| Kaijie bio medicine Peptide APIs |
- What are the similarities and differences between shengnuo biotechnology companies + CDMO companies? Who has more potential in the future?
- Analysis of China’s peptide drug market scale and industry development trend in 2021
- Shengnuo Biotechnologynology focuses on the field of peptide APIs and preparations
- Shengnuo Biotechnologytechnology IPO: Peptide CDMO has outstanding competitive advantages, product line covers multiple fields
- Shengnuo Biotechnologytechnology Science and Technology Innovation Board is listed to strengthen the two-way competitive advantage of peptide innovative drug pharmaceutical research services and independent peptide drug products
English
Arabic
Dutch
French
German
Italian
Japanese
Latin
Portuguese
Russian
Spanish